Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Hoffmann-La Roche
AstraZeneca
Hoffmann-La Roche
Bristol-Myers Squibb
National Cancer Institute (NCI)
Hoffmann-La Roche
Gilead Sciences
AstraZeneca
Byondis B.V.
Nektar Therapeutics
Gilead Sciences
Children's Oncology Group
Merck Sharp & Dohme LLC
Children's Oncology Group
CTI BioPharma
Boehringer Ingelheim
GOG Foundation
Novartis
Alliance for Clinical Trials in Oncology
Eli Lilly and Company
New Mexico Cancer Research Alliance
H. Lee Moffitt Cancer Center and Research Institute
Merck KGaA, Darmstadt, Germany